查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1540932

2024-2032 年葡萄膜炎治疗市场报告（依治疗类型、疾病类型、病因、配销通路和地区）

Uveitis Treatment Market Report by Treatment Type, Disease Type, Cause, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球葡萄膜炎治疗市场规模达17亿美元。由于葡萄膜炎发病率上升、各种生物製剂和免疫抑制治疗的持续研发活动以使治疗可能性多样化、更加重视提高认识和早期诊断、有利的政府政策和医疗保健报销，市场正在经历显着增长。

葡萄膜炎治疗市场分析：

主要市场驱动因素：葡萄膜炎治疗市场主要受到全球自体免疫疾病和发炎性疾病发生率上升的推动。由于它经常导致葡萄膜炎，因此越来越多的人需要药物来减轻发炎并保护眼睛免于进一步恶化，从而促进市场成长。

主要市场趋势：葡萄膜炎治疗市场的主要趋势包括迅速转向使用生物製剂和标靶疗法来治疗葡萄膜炎。与传统疗法相比，这些疗法表现出对目标行动的更深入理解，甚至可能更少程度地产生不良后果。此外，葡萄膜炎药物输送方法的改进，例如缓释植入物，在葡萄膜炎的治疗中提供了更好的效果，并提高了患者的依从性。

地理趋势：北美占据葡萄膜炎治疗市场的最大份额。这得益于该地区发达的医疗保健系统、坚持早期使用新兴疗法以及对研发的大量投资。临床试验中主要市场参与者和学术机构中心的存在支持北美在葡萄膜炎更好的治疗进展方面处于领先地位。

竞争格局：葡萄膜炎治疗产业的一些主要市场参与者包括AbbVie Inc.、Alimera Sciences Inc.、Bausch & Lomb Incorporated (Bausch Health)、Enzo Biochem Inc.、Eyegate Pharmaceuticals Inc.、Eyepoint Pharmaceuticals Inc.、Novartis AGAG 、Regeneron Pharmaceuticals Inc.、参天製药有限公司等。

挑战与机会：葡萄膜炎治疗市场的成长面临着治疗成本高、用于治疗疾病的药物审批程序复杂等挑战。然而，机会在于医疗供应，特别是在快速成长的经济体中，以及为葡萄膜炎患者开发新治疗方法的持续研究。

葡萄膜炎治疗市场趋势：

自体免疫疾病的盛行率不断增加

全球自体免疫疾病发生率的增加刺激了葡萄膜炎治疗的需求。根据美国国立卫生研究院 (NIH) 报告，自体免疫疾病估计影响 2,350 万美国人，他们患有类风湿性关节炎、发炎性肠道疾病和狼疮等疾病，并继发葡萄膜炎。值得注意的是，这种流行证明了对针对自体免疫疾病的有效葡萄膜炎疗法的高需求并刺激了市场需求。因此，随着这些疾病在世界各地的流行，治疗的目标是葡萄膜炎及其控制症状的疗法，并解决导致疾病在患者生活中取得更好结果的自身免疫过程。

生物製剂和免疫疗法的进展

生物製剂和免疫调节疗法透过调节免疫介导的过程彻底改变了葡萄膜炎的治疗。美国国立卫生研究院 (NIH) 已批准多种用于治疗葡萄膜炎等自体免疫疾病的生物製剂，这标誌着人们开始转向使用经济有效的生物製剂。与皮质类固醇等其他治疗方法相比，此类疗法具有较低的副作用影响身体其他器官的可能性，这反过来又见证了患者更愿意接受向他们推荐的治疗方案。因此，生物技术和免疫学市场持续存在，导致生物製剂和免疫调节剂的产品开发，扩大了全球市场葡萄膜炎治疗的机会。

医疗保健支出和研究经费不断增加

政府在医疗保健系统、发展策略和医疗保健进步方面支出的增加正在推动葡萄膜炎治疗的市场价值。在美国，美国国立卫生研究院 (NIH) 支持大量资金来研究葡萄膜炎和其他自体免疫疾病，这项研究是大学、製药业和医院之间的多部门、多方合作。这种财政支持进一步为葡萄膜炎新疗法的进展带来积极的变化，推动新药、生物製剂和治疗方法的开发。此外，政府支持的研究拨款和临床试验提供了必要的框架和资源，以支持探索新的治疗方案并验证治疗的有效性。这些动态使得葡萄膜炎治疗市场高度研究密集，因为它利用将发现转化为临床有用的产品和服务，满足现有需求并增强全球患者的体验。

葡萄膜炎治疗市场细分：

IMARC Group提供了每个细分市场的主要趋势分析，以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据治疗类型、疾病类型、病因和配销通路对市场进行了分类。

按治疗类型细分：

皮质类固醇

免疫抑制剂

单株抗体

睫状肌麻痹剂

抗生素

抗病毒药

抗真菌剂

止痛药

皮质类固醇占大部分市场份额

该报告根据治疗类型对市场进行了详细的细分和分析。这包括皮质类固醇、免疫抑制剂、单株抗体、睫状肌麻痹剂、抗生素、抗病毒药、抗霉菌药和止痛药。根据该报告，皮质类固醇占最大部分。

根据葡萄膜炎治疗市场预测，皮质类固醇在葡萄膜炎治疗市场中占据主导地位，因为它们有助于减少受影响个体的发炎并保持视力。美国国立卫生研究院(NIH) 报告称，皮质类固醇是葡萄膜炎的主要治疗方法，因为它们可以快速控制发炎和不同葡萄膜炎类型（前葡萄膜炎、后葡萄膜炎和全葡萄膜炎）的体征。这些药物的主要适应症是降低身体抵抗眼部感染的能力并减少炎症，从而提供快速有效的缓解并提高患者的健康程度。根据病情的严重程度和患者的病情，可以透过眼药水、注射剂和口服片剂给予皮质类固醇。由于皮质类固醇可能存在副作用，包括长期使用导致眼压升高和术后白内障形成，因此它们仍然优于其他竞争对手，而中等有效的局部非类固醇抗发炎药物在葡萄膜炎治疗中并不那么受欢迎，儘管在眼科实践中经常使用。

按疾病类型细分：

前葡萄膜炎

后葡萄膜炎

中间葡萄膜炎

全葡萄膜炎

前葡萄膜炎产业占最大

报告还根据疾病类型对市场进行了详细的细分和分析。这包括前葡萄膜炎、后葡萄膜炎、中间葡萄膜炎和全葡萄膜炎。报告称，前葡萄膜炎占最大的市场份额。

前葡萄膜炎因其发病率较高且需要独特的治疗方法而在葡萄膜炎治疗细分领域占据领先地位。美国国立卫生研究院 (NIH) 将前葡萄膜炎归类为最常见的葡萄膜炎类型，占美国报告的所有葡萄膜炎的 50-60%。这是由眼睛前部（称为葡萄膜）的结构性发炎引起的，它与自体免疫疾病、感染或身体损伤有关。因此，这种模式意味着前葡萄膜炎的治疗需要不同的管理策略，例如局部皮质类固醇和扩瞳剂，在诊所或眼科和零售店进行常规管理，从而创造有利的治疗效果

分手原因：

传染性

非传染性

非感染性代表领先的细分市场

该报告根据原因对市场进行了详细的细分和分析。这包括传染性和非传染性。根据该报告，非传染性占最大部分。

非感染性葡萄膜炎治疗市场收入成长，因为这种疾病比感染相关的疾病更常见，并且透过改进针对自体免疫和发炎过程的实证个体化治疗来解决。根据美国国立卫生研究院 (NIH) 的数据，在美国，非感染性葡萄膜炎约占所有葡萄膜炎病例的 80-90%。这种形式的葡萄膜炎与类风湿性关节炎、发炎性肠道疾病、狼疮等自体免疫疾病更相关，并且需要生物製剂和免疫调节剂。世界各地的研究人员观察到，自体免疫疾病的病例不断增加，这加强了非感染性葡萄膜炎治疗的市场地位。现代製药业专注于开发适当的个人化抗视网膜製剂，以更有效地针对非感染性葡萄膜炎的免疫致病背景，同时将全身给药的副作用降至最低，从而创造良好的葡萄膜炎治疗市场前景。

按配销通路划分：

医院药房

零售药局

网路药局

其他的

零售药局在市场上表现出明显的主导地位

报告还提供了基于配销通路的详细市场细分和分析。这包括医院药房、零售药房、线上药房等。报告显示，零售药局占据了最大的市场份额。

零售药局在葡萄膜炎治疗中占有最大的市场份额，主要是因为它们容易取得、方便，尤其是对患者而言，而且它们也从事药物配发。美国社区药剂师协会 (NCPA) 报告称，美国约 72% 的处方是由零售药房配发的，这强调了药剂师在配药过程中的中心地位。葡萄膜炎治疗市场概况表明，被诊断为葡萄膜炎的患者可以方便且快速地从零售药房获得处方药，如皮质类固醇、免疫抑制剂和生物製剂。此外，零售药局还涉及患者咨询、药物和健康保险资讯及管理，从而提高患者满意度和治疗效果。利害关係人使用它们与卫生系统和电子健康记录进行交互，从而为葡萄膜炎患者提供连续性护理。由于零售药房的服务日益多样化以及对患者和消费者的关注日益深入，它们为满足葡萄膜炎药物市场日益增长的需求做出了巨大贡献，并主导了药物的分销。

按地区划分：

北美洲

美国

加拿大

亚太地区

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美市场领先，占最大的葡萄膜炎治疗市场份额

该报告还对所有主要区域市场进行了全面分析，包括北美（美国和加拿大）、亚太地区（中国、日本、印度、韩国、澳洲、印尼等）、欧洲（德国） 、法国、英国、义大利、西班牙、俄罗斯等）、拉丁美洲（巴西、墨西哥等）以及中东和非洲。报告称，北美是葡萄膜炎治疗的最大区域市场。

根据葡萄膜炎治疗市场报告，北美因其发达和先进的医疗保健行业、接受新颖的治疗管理以及直接的研发支出而占据最大的市场份额。根据美国国立卫生研究院 (NIH) 报告，仅在美国就有大量预算专门用于自体免疫疾病研究，并且各製药实体、研究机构和护理人员之间存在有利于大量临床试验和合作的环境。这种策略性投资使北美国家能够在生物製剂、免疫调节剂和其他葡萄膜炎治疗方法的开发和商业化方面处于领先地位。此外，由于自体免疫疾病后来发展为葡萄膜炎的频率较高，北美地区需要有效的葡萄膜炎治疗和管理，以维持全球葡萄膜炎市场的市场领导地位。

竞争格局：

市场研究报告也对市场竞争格局进行了全面分析。也提供了所有主要公司的详细资料。葡萄膜炎治疗产业的一些主要市场参与者包括 AbbVie Inc.、Alimera Sciences Inc.、Bausch & Lomb Incorporated (Bausch Health)、Enzo Biochem Inc.、Eyegate Pharmaceuticals Inc.、Eyepoint Pharmaceuticals Inc.、Novartis AG、Regeneron Pharmaceuticals株式会社、参天製药株式会社

（请注意，这只是关键参与者的部分列表，报告中提供了完整列表。）

葡萄膜炎治疗公司包括製药公司和研究机构都专注于葡萄膜炎治疗的发展，透过临床试验来应对葡萄膜炎疾病过程中提出的各种挑战。艾伯维 (AbbVie)、诺华 (Novartis) 和艾尔建 (Allergan) 等市场领导者致力于研发推出针对葡萄膜炎发展的特定免疫过程的新药。例如，艾伯维（AbbVie）的研究策略涉及最近的合作和临床试验，探索生物製剂在自体免疫性葡萄膜炎中的应用，证明了对精准医疗的关注。其中许多活动都是透过政府和研究资助来资助的，这些资助促进了学术与产业的合作，以在葡萄膜炎治疗范式转变的背景下推进治疗进展并改善患者的护理，从而推动葡萄膜炎治疗行业的成长。

葡萄膜炎治疗市场新闻：

2024 年 4 月，Brepocitinib 在一项 2 期研究中显示出治疗非感染性葡萄膜炎的正面结果，显示出在减少发炎和改善患者预后方面的良好疗效。

本报告回答的关键问题

  • 2023年全球葡萄膜炎治疗市场规模是多少
  • 2024-2032年全球葡萄膜炎治疗市场的预期成长率是多少
  • COVID-19 对全球葡萄膜炎治疗市场有何影响
  • 推动全球葡萄膜炎治疗市场的关键因素是什么
  • 根据治疗类型，全球葡萄膜炎治疗市场的细分如何
  • 根据疾病类型，全球葡萄膜炎治疗市场的细分如何
  • 全球葡萄膜炎治疗市场的分裂原因是什么
  • 基于配销通路的全球葡萄膜炎治疗市场的细分是什么
  • 全球葡萄膜炎治疗市场的重点区域有哪些
  • 10. 全球葡萄膜炎治疗市场的主要参与者/公司有哪些？

本报告回答的关键问题

  • 2023年全球葡萄膜炎治疗市场规模有多大？ 2024-2032年全球葡萄膜炎治疗市场的预期成长率是多少？
  • COVID-19 对全球葡萄膜炎治疗市场有何影响？
  • 推动全球葡萄膜炎治疗市场的关键因素是什么？
  • 根据治疗类型，全球葡萄膜炎治疗市场的细分情况如何？
  • 根据疾病类型，全球葡萄膜炎治疗市场的细分情况如何？
  • 全球葡萄膜炎治疗市场的分裂原因是什么？
  • 根据配销通路，全球葡萄膜炎治疗市场的细分情况如何？
  • 全球葡萄膜炎治疗市场的关键地区有哪些？
  • 全球葡萄膜炎治疗市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球葡萄膜炎治疗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依治疗类型

  • 皮质类固醇
    • 市场趋势
    • 市场预测
  • 免疫抑制剂
    • 市场趋势
    • 市场预测
  • 单株抗体
    • 市场趋势
    • 市场预测
  • 睫状肌麻痹剂
    • 市场趋势
    • 市场预测
  • 抗生素
    • 市场趋势
    • 市场预测
  • 抗病毒药
    • 市场趋势
    • 市场预测
  • 抗真菌剂
    • 市场趋势
    • 市场预测
  • 止痛药
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依疾病类型

  • 前葡萄膜炎
    • 市场趋势
    • 市场预测
  • 后葡萄膜炎
    • 市场趋势
    • 市场预测
  • 中间葡萄膜炎
    • 市场趋势
    • 市场预测
  • 全葡萄膜炎
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按原因

  • 传染性
    • 市场趋势
    • 市场预测
  • 非传染性
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按配销通路

  • 医院药房
    • 市场趋势
    • 市场预测
  • 零售药局
    • 市场趋势
    • 市场预测
  • 网路药局
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • Alimera Sciences Inc.
    • Bausch & Lomb Incorporated (Bausch Health)
    • Enzo Biochem Inc.
    • Eyegate Pharmaceuticals Inc.
    • Eyepoint pharmaceuticals Inc.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc
    • Santen Pharmaceutical Co. Ltd.
Product Code: SR112024A2759

The global uveitis treatment market size reached US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.6 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032. The market is experiencing significant growth driven by the rising incidence of uveitis, ongoing research and development activities in various biologics and immunosuppressive treatments to diversify treatment possibilities, heightening emphasis on increasing awareness and early diagnosis, favorable government policies, and healthcare reimbursements.

Uveitis Treatment Market Analysis:

Major Market Drivers: The uveitis treatment market is primarily driven by the rising rates of autoimmune disorders and inflammatory illnesses globally. Since it results in uveitis often, there is increasing incidences of people in need of medication that can reduce inflammation and protect the eyes from further deterioration, thus contributing to market growth.

Key Market Trends: The key uveitis treatment market trends include a rapid shift toward the use of biologics and targeted therapies for the management of uveitis. In comparison to the conventional treatments, these therapies demonstrate a closer understanding of the targeted actions and possibly even less levels of undesired consequences. Further, improved methods of drug delivery in uveitis such as sustained-release implants are providing better results in the therapy of uveitis and higher patient compliance.

Geographical Trends: North America holds the largest share of the uveitis treatment market. This is due to the region's well-developed health care system, the insistence of the early use of emerging treatments, and large investments in research and development. The existence of hubs of key market players and academic institutions in clinical trials supports North America as a lead in the progress of better treatments for uveitis.

Competitive Landscape: Some of the major market players in the uveitis treatment industry include AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., among many others.

Challenges and Opportunities: The uveitis treatment market growth faces challenges such as high costs of treatment and complicated procedures for approval of drugs used for the treatment of the condition. However, the opportunities lie in the medical provisions, especially in the fast-growing economies and in the continual research to develop new treatment methods for uveitis patients.

Uveitis Treatment Market Trends:

Increasing Prevalence of Autoimmune Diseases

The uveitis treatment demand is stimulated by the increased rate of autoimmune diseases all over the world. As reported by the National Institutes of Health (NIH), autoimmune diseases are estimated to affect 23.5 million Americans, who have rheumatoid arthritis, inflammatory bowel disease, and lupus among other diseases develop uveitis as a sequel. It is important to note that this prevalence proves the high requirement for efficient uveitis therapies targeted at autoimmune diseases and stimulating the demand in the market. Thus, as these diseases move high across the world, treatment aims for uveitis and its therapies controlling the symptoms and it addresses the autoimmune processes that cause the disease to achieve better results in patients' lives.

Advancements in Biologics and Immunotherapy Therapies

Biologics and immunomodulatory therapies have revolutionized uveitis management by modulation of immune-mediated processes. The National Institutes of Health (NIH) has approved various biologics for autoimmune diseases, such as uveitis, signifying the change towards the use of cost-effective and effective biologics. Such therapies have benefits such as lower probability of side effects affecting other organs in the body than other treatments like corticosteroids which in turn is witnessing patients being more compliant to the treatment regimens that are recommended to them. As a result, there are continued markets in biotechnology and immunology leading to product development in biologics and immunomodulators extending the opportunities for the treatment of uveitis in the global market.

Rising Healthcare Expenditure and Research Funding

Increased government spending in healthcare systems, development strategies, and advances in healthcare are fueling the uveitis treatment market value. In the USA, the NIH supports significant funding to investigate uveitis and other auto-immune disorders, and this research has been a multisectoral and multiparty cooperation among universities, pharmaceutical industries, and hospitals. This financial support further brings a positive change to the progression of new treatments for uveitis as it pushes the development of new drugs, biologics, and treatment methods. Moreover, research grants and clinical trials that are supported by the government offer essential frameworks and resources to support the exploration of novel therapeutic profiles and verify the effectiveness of treatments. These dynamics make the uveitis treatment market highly research-intensive, as it capitalizes on the conversion of discoveries into clinically useful products and services that address existing requirements and enhance patient experience worldwide.

Uveitis Treatment Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on treatment type, disease type, cause, and distribution channel.

Breakup by Treatment Type:

Corticosteroids

Immunosuppressant

Monoclonal Antibodies

Cycloplegic Agents

Antibiotics

Antivirals

Antifungal

Analgesics

Corticosteroids account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the treatment type. This includes corticosteroids, immunosuppressant, monoclonal antibodies, cycloplegic agents, antibiotics, antivirals, antifungal, and analgesics. According to the report, corticosteroids represented the largest segment.

As per the uveitis treatment market forecast, Corticosteroids thus dominate the uveitis treatment market by share since they help reduce inflammation and maintain vision in affected individuals. The National Institutes of Health (NIH) reported that corticosteroids are the primary therapy for uveitis, as they yield fast control of inflammation and signs about different uveitis types, anterior, posterior, and panuveitis. The main indications for these medicines are to lessen the body's ability to fight infection in the eye and diminish inflammation, which provides fast and effective relief and enhances the degree of patient's health. Corticosteroids can be administered through eye drops, injections, and oral tablets depending on the intensity of the situation and condition of the patient. As corticosteroids present possible side-effects, including rising intraocular pressure and postoperative cataract formation by long-term application, they remain preferred to other competitors while moderately effective topical NSAIDs are not as popular in uveitis treatment despite frequent use in ophthalmological practice.

Breakup by Disease Type:

Anterior Uveitis

Posterior Uveitis

Intermediate Uveitis

Panuveitis

Anterior uveitis holds the largest share of the industry

A detailed breakup and analysis of the market based on the disease type have also been provided in the report. This includes anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis. According to the report, anterior uveitis accounted for the largest market share.

Anterior uveitis holds a leading position in the segmentation of uveitis treatment because of its greater incidence and the necessity of unique therapy. The National Institutes of Health (NIH) categorizes anterior uveitis as the most prevalent type of uveitis which accounts for 50-60% of all uveitis reported in the United States. This is caused by inflammation of the structures of the anterior part of the eye known as the uvea, it is linked with autoimmune diseases, infections, or physical injury. As a result, the pattern implies the treatment of anterior uveitis requires different management strategies such as topical corticosteroids and pupil-dilating agents available, routinely managed in clinics or ophthalmology and retail outlets, thus creating a favorable

Breakup by Cause:

Infectious

Non-infectious

Non-infectious represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the cause. This includes infectious and non-infectious. According to the report, non-infectious represented the largest segment.

Non-infectious drive the uveitis treatment market revenue as the condition is more frequent than the infection-related kind and was addressed using improving evidence-based individualized treatment targeting autoimmune and inflammation processes. According to the National Institutes of Health (NIH), non-infectious uveitis accounts for approximately 80-90% of all uveitis cases in the United States. This form of uveitis is more related to autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, lupus, and the need for biologics and immunomodulatory agents. It has been observed by researchers from across the world that the cases of autoimmune diseases are continuously increasing, which strengthens the market position of the non-infectious forms of uveitis treatments. The modern pharmaceutical industry concentrates on the development of proper individual antiretirologic preparations to target more effectively the immunopathogenetic background of non-infectious uveitis with minimal side effects from systemic administration, thus creating a favorable uveitis treatment market outlook.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Retail pharmacies exhibit a clear dominance in the market

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital pharmacies, retail pharmacies, online pharmacies, and others. According to the report, retail pharmacies accounted for the largest market share.

Retail pharmacies hold the largest market share of uveitis treatment primarily because they are easily accessible, and convenient, especially to the patients and they also engage in the dispensing of drugs. The National Community Pharmacists Association (NCPA) repoted that retail pharmacies in the United States dispense about 72% of prescriptions emphasizing the centrality of pharmacists in dispensing of medication. This uveitis treatment market overview shows that patients diagnosed with uveitis can conveniently get prescribed medicines such as corticosteroid, immunosuppressant, and biologic agents from the retail pharmacy at a faster pace. Additionally, retail pharmacies involve patient counseling, medication and health insurance information and management, which improves patient satisfaction and outcomes. Stakeholders use them to interface with the health systems and electronic health records, thereby providing continuity of care to patients with uveitis. Due to increased diversification of services and sophisticated patient and consumer focus in retail pharmacy, they significantly contribute to meeting the increasing needs of the market for uveitis medications and dominating the distribution of drugs.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest uveitis treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil Mexico, and others) and the Middle East and Africa. According to the report, North America was the largest regional market for uveitis treatment.

As per the uveitis treatment market report, North America holds the largest market share due to its well-developed and advanced healthcare sector, acceptance of novel therapeutic management, and direct spending on research and development. As reported by the National Institutes of Health (NIH), a significant budget is devoted to autoimmune disease studies in the United States alone and there exists a conducive environment for numerous clinical trials and partnerships among various pharmaceutical entities, research institutions, and caregivers. Such strategic investment allows North American countries to take a frontline in the development and commercialization of biologics, immunomodulatory, and other approaches to treating uveitis. Also, presenting a higher frequency of autoimmune diseases which later develop into uveitis, the North American region needs efficient uveitis treatment and management, thereby carrying the market leadership of the global uveitis market.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the uveitis treatment industry include AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc., and Santen Pharmaceutical Co. Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The uveitis treatment companies are focusing on the development of uveitis treatment include pharmaceutical companies and research institutions to meet the various challenges presented by the uveitis disease process through clinical trials. The market leaders such as AbbVie, Novartis, and Allergan are committed to research and development to launch new drugs that address specific immunological processes of uveitis development. For instance, the research strategies of AbbVie involve recent collaborations and clinical trials that explore the usage of biologics for autoimmune uveitis, proving the focus on precision medicine. Many of these activities are funded through government and research grants that promote academic-industry collaboration to advance therapeutic progress and improve patients' care in the context of the shifting uveitis treatment paradigm, thus fueling uveitis treatment industry growth.

Uveitis Treatment Market News:

In April 2024, Brepocitinib demonstrated positive results for treating non-infectious uveitis in a Phase 2 study, showing promising efficacy in reducing inflammation and improving patient outcomes.

Key Questions Answered in This Report

  • 1. What was the size of the global uveitis treatment market in 2023?
  • 2. What is the expected growth rate of the global uveitis treatment market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global uveitis treatment market?
  • 4. What are the key factors driving the global uveitis treatment market?
  • 5. What is the breakup of the global uveitis treatment market based on the treatment type?
  • 6. What is the breakup of the global uveitis treatment market based on the disease type?
  • 7. What is the breakup of the global uveitis treatment market based on the cause?
  • 8. What is the breakup of the global uveitis treatment market based on the distribution channel?
  • 9. What are the key regions in the global uveitis treatment market?
  • 10. Who are the key players/companies in the global uveitis treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Uveitis Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Corticosteroids
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunosuppressant
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Monoclonal Antibodies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Cycloplegic Agents
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antibiotics
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Antivirals
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Antifungal
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Analgesics
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Anterior Uveitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Posterior Uveitis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intermediate Uveitis
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Panuveitis
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Cause

  • 8.1 Infectious
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Non-infectious
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alimera Sciences Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Bausch & Lomb Incorporated (Bausch Health)
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 Enzo Biochem Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Eyegate Pharmaceuticals Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Eyepoint pharmaceuticals Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Novartis AG
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Regeneron Pharmaceuticals Inc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Santen Pharmaceutical Co. Ltd.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Uveitis Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Uveitis Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Uveitis Treatment Market: Breakup by Treatment Type (in %), 2023
  • Figure 4: Global: Uveitis Treatment Market: Breakup by Disease Type (in %), 2023
  • Figure 5: Global: Uveitis Treatment Market: Breakup by Cause (in %), 2023
  • Figure 6: Global: Uveitis Treatment Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Uveitis Treatment Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Uveitis Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Uveitis Treatment (Corticosteroids) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Uveitis Treatment (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Uveitis Treatment (Immunosuppressant) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Uveitis Treatment (Immunosuppressant) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Uveitis Treatment (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Uveitis Treatment (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Uveitis Treatment (Cycloplegic Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Uveitis Treatment (Cycloplegic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Uveitis Treatment (Antibiotics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Uveitis Treatment (Antibiotics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Uveitis Treatment (Antivirals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Uveitis Treatment (Antivirals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Uveitis Treatment (Antifungal) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Uveitis Treatment (Antifungal) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Uveitis Treatment (Analgesics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Uveitis Treatment (Analgesics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Uveitis Treatment (Anterior Uveitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Uveitis Treatment (Anterior Uveitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Uveitis Treatment (Posterior Uveitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Uveitis Treatment (Posterior Uveitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Uveitis Treatment (Intermediate Uveitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Uveitis Treatment (Intermediate Uveitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Uveitis Treatment (Panuveitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Uveitis Treatment (Panuveitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Uveitis Treatment (Infectious) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Uveitis Treatment (Infectious) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Uveitis Treatment (Non-infectious) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Uveitis Treatment (Non-infectious) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Uveitis Treatment (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Uveitis Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Uveitis Treatment (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Uveitis Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Uveitis Treatment (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Uveitis Treatment (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Global: Uveitis Treatment (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Global: Uveitis Treatment (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: North America: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: North America: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: United States: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: United States: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Canada: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Canada: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Asia Pacific: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Asia Pacific: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: China: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: China: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Japan: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Japan: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: India: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: India: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: South Korea: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: South Korea: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Australia: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Australia: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Indonesia: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Indonesia: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Others: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Others: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Europe: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Europe: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Germany: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Germany: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: France: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: France: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: United Kingdom: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: United Kingdom: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Italy: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Italy: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Spain: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Spain: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Russia: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Russia: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Others: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Others: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Latin America: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Latin America: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Brazil: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Brazil: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Mexico: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Mexico: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Others: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Others: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 91: Middle East and Africa: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 92: Middle East and Africa: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Global: Uveitis Treatment Industry: SWOT Analysis
  • Figure 94: Global: Uveitis Treatment Industry: Value Chain Analysis
  • Figure 95: Global: Uveitis Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Uveitis Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Uveitis Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 3: Global: Uveitis Treatment Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 4: Global: Uveitis Treatment Market Forecast: Breakup by Cause (in Million US$), 2024-2032
  • Table 5: Global: Uveitis Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Uveitis Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Uveitis Treatment Market Structure
  • Table 8: Global: Uveitis Treatment Market: Key Players